Skip to main content

Reevaluation of Conventional Pituitary Irradiation in the Therapy of Acromegaly

Abstract

External beam pituitary irradiation has been frequently used in the treatment of growth hormone (GH) secreting pituitary adenomas. Many studies have demonstrated that serum GH declines rapidly and reliably following treatment and early “cure” rates, based on a basal serum GH below 10 µg/L were as high as 80%. The definition of “cure” has become more stringent over time and retrospective studies have indicated that GH must be below 2.5 µg/L for acromegalics to achieve mortality rates comparable to a normal population. Only 20% of irradiated patients will achieve this goal by 10 yr. Even fewer will achieve a normal serum insulin-like growth factor I (IGF-I) levels. Although pituitary irradiation still has a role in the control of tumor size, its importance as a treatment for normalizing serum GH is being reevaluated.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Clayton RN. New developments in the management of acromegaly. Should we achieve absolute biochemical cure. J Endocrinol 1997;155: S23-S29.

    Google Scholar 

  2. 2.

    Laws ER, Piepgras DG, Randall RV, Abboud CF. Neurosurgical management of acromegaly. Results in 82 patients treated between 1972 and 1977. J Neurosurg 1979;50: 454–461.

    Google Scholar 

  3. 3.

    Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21:713–735.

    Google Scholar 

  4. 4.

    Fahlbusch R, Honegger J, Buchfelder M. Evidence supporting surgery as treatment of choice for acromegaly. J Endo-crinol 1997;155:S53–55.

    Google Scholar 

  5. 5.

    Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly. Clin Endocrinol 1995;517–522.

  6. 6.

    Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med1993;86: 293–299.

    Google Scholar 

  7. 7.

    Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95–102.

    Google Scholar 

  8. 8.

    Wrightson P, Rajasoorya C, Holdaway M Scott J. Acromegaly: Factors affecting the long-term outcome after surgical treatment. J Clin Neurosci 1994;1:164–172.

    Google Scholar 

  9. 9.

    Jaffe CA, Turgeon DK, DeMott Friberg R, Watkins PB, Barkan AL.Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: Potential involvement of endogenous somatostatin. J Clin Endocrinol Metabol 1995; 80:3321–3326.

    Google Scholar 

  10. 10.

    Jaffe CA, Ocampo-Lim BN, Krueger K, Sugahara I, Mauger DT, DeMott-Friberg R, Barkan AL. Sexual dimorphism of growth hormone secretion and regulation in humans. J Clin Invest 1998;102:153–164.

    Google Scholar 

  11. 11.

    Chang-DeMoranville BM, Jackson IMD. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am 1992;21:649–668.

    Google Scholar 

  12. 12.

    Chapman IM, Hartman M, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994;78:1312–1319.

    Google Scholar 

  13. 13.

    Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-c in acromegaly: Correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67:69–73.

    Google Scholar 

  14. 14.

    Daughaday WH, Starkey RH, Saltman S, Gavin III JR, Mills-Dunlop B, Health-Monnig E. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab 1987;65–617–623.

    Google Scholar 

  15. 15.

    Brockmeier SJ, Buchfelder M, Adams EF, Schott W, Fahlbusch R. Acromegaly with 'normal' serum growth hormone levels. Clinical features, diagnosis and results of transsphenoidal microsurgery. Horm Metabol Res 1992;24: 392–400.

    Google Scholar 

  16. 16.

    Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, DeMott Friberg R, Chandler WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187–3191.

    Google Scholar 

  17. 17.

    Spagnoli A, Rosenfeld RG. The mechanisms by which growth hormone brings about growth. Endocrinol Metab Clin North Am 1996;25:615–631.

    Google Scholar 

  18. 18.

    Eastman TC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992;21:693–712.

    Google Scholar 

  19. 19.

    Halberg FE, Sheline GE. Radiotherapy of pituitary tumors. Endocrinol Metab Clin North Am 1987;16:667–684.

    Google Scholar 

  20. 20.

    Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, Padfield PL, Edwards CR. How effective is external pituitary irra-diation for growth hormone-secreting pituitary tumors? Clin Endocrinol 1984;20:401–408.

    Google Scholar 

  21. 21.

    Goffman TE, Dewan R, Arakaki R, Gorden P, Oldfield EH, Glatstein E. Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safety of postsurgical radiation therapy. Cancer 1992;69:271–275.

    Google Scholar 

  22. 22.

    Speirs CJ, Reed PI, Morrison R, Aber V, Joplin GF. The effectiveness of external beam radiotherapy for acromegaly is not affected by previous pituitary ablative treatments. Acta Endocrinol (Copenh) 1990;122:559–565.

    Google Scholar 

  23. 23.

    Sheline GF. Conventional radiation therapy in the treatment of pituitary tumors. In [Editor(s)?]. Clinical Management of Pituitary Disorders New York: Raven Press, 1979;287.

    Google Scholar 

  24. 24.

    Werner S, Af Trampe E, Palacios P, Lax I, Hall K. Growth hormone producing pituitary adenomas with concomitant hypersecretion of prolactin are particularly sensitive to photon irradiation. Int J Radiant Oncol Biol Phys 1985;11: 1713–1720.

    Google Scholar 

  25. 25.

    Wass JA, Moult PJ, Thorner MO, Dacie JE, Charlesworth M, Jones AE, Besser GM. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 1979; 2(8133):66–69.

    Google Scholar 

  26. 26.

    Littley MD, Shalet SM, Swindell, Beardwell CG, Sutton ML. Low-dose pituitary irradiation for acromegaly. Clin Endocrinol 1990;32:261–270.

    Google Scholar 

  27. 27.

    Baldwin A, Cundy T, Butler J, et al. Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation. Act Endocrinol (Copenh) 1985;108: 26–30.

    Google Scholar 

  28. 28.

    Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 1979;48:931–940.

    Google Scholar 

  29. 29.

    Lombardi G, Colao A, Marzullo P, Ferone D, Longobardi S, Esposito V, Merola B. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 1997;155:S33-S37.

    Google Scholar 

  30. 30.

    MacSweeney JE, Baxter MA, Joplin GF. Heel pad thickness is an insensitive index of biochemical remission in acromegaly. Clin Radiol 1990;42:348–350.

    Google Scholar 

  31. 31.

    Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients; an ultrasonography study. J Clin Endocrinol Metab 1998;83:212–215.

    Google Scholar 

  32. 32.

    Jaffe CA, Barkan AL. Acromegaly: Recognition and drug treatment. Drugs 1994;47:425–445.

    Google Scholar 

  33. 33.

    Ciccarelli E, Valett MR, Vasario E, Avateneo T, Grottoli S, Camanni F. Hormonal and radiologic effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Endocrinol Invest 1993;16:565–572.

    Google Scholar 

  34. 34.

    af Traupe E, Lundell G, Lax I, Werner S. External irradiation of growth hormone producing pituitary adenomas: Prolactin as a marker of hypothalamic and pituitary effects. Int J Radiat Oncol Biol Phys 1991;20:655–660.

    Google Scholar 

  35. 35.

    Thalassinos NC, Tsagarakis S, Ioannides G, Tzavara I, Papavasiliou C. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: A long term follow-up study. Eur J Endocrinol 1998;138:160–163.

    Google Scholar 

  36. 36.

    Lucas T, Brito M, Estrada J, Alcaniz A, Magallon R, G-Uria J, Barcelo B. Conventional radiotherapy in the treatment of acromegaly: Is it a choice? Program of the Fifth International Pituitary Congress; June 28–30, 1998; Naples, FL;33.

    Google Scholar 

  37. 37.

    Ludecke DK, Lutz BS, Niedworok G. The choice of treatment after incomplete adenomectomy in acromegaly: Proton versus highvoltage radiation. Act Neurochir 1989;96:32–38.

    Google Scholar 

  38. 38.

    Thoren M, Rahn T, Guo WY, Werner S. Stereotactic radiosurgery with the cobalt-60 gamma unit in the treatment of growth hormone-producing pituitary tumors. Neurosurgery 1991;29:663–668.

    Google Scholar 

  39. 39.

    Vance ML, Woodburn J, Steiner L, Laws ER. Gamma knife radiation for functinal pituitary adenomas. In 80th Annual Meeting of the Endocrine Society, New Orleans, LA, 1998; 400.

  40. 40.

    Howatt TA, Plowman PN, Wass JA, Rees LH, Jones AE, Besser GM. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: Long term follow-up. Clin Endocrinol 1989;31:309–323.

    Google Scholar 

  41. 41.

    Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971;285:243–247.

    Google Scholar 

  42. 42.

    Estrada J, Boronat M, Mielgo M, et al. The long-term out-come of pituitary irradiation after unsuccessful transsphe-noidal surgery in Cushing's disease. N Engl J Med 1997; 336:172–177.

    Google Scholar 

  43. 43.

    Tsagarakis S, Grossman A, Plowman PN, et al. Megavoltage pituitary irradiation in the management of prolactinomas: Long-term follow-up. Clin Endocrinol 1991;34:399–406.

  44. 44.

    Tsang RW, Brierley JD, Panzarell T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Role of radiation therapy in clinically hormonally-active pituitary adenomas. Radioth Oncol 1996;41:45–53.

    Google Scholar 

  45. 45.

    Snyder PJ, Fowbel BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81:457–462.

    Google Scholar 

  46. 46.

    Macleod AF, Clarke DG, Pambakian H, Lowy C, Sonksen PH, Collins CD. Treatment of acromegaly by external irra-diation. Clin Endocrinol 1989;30:303–314.

    Google Scholar 

  47. 47.

    Littley MD, Shalet SM, Swindell R, Beardwell CG, Sutton ML. Low-dose pituitary irradiation for acromegaly. Clin Endocrinol 1990;32:261–270.

    Google Scholar 

  48. 48.

    Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M. External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys 1995;33:307–314.

    Google Scholar 

  49. 49.

    Littley MD, Shalet SM, Beardwell CG, Robinson EL, Sutton ML. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol 1989;31:363–373.

    Google Scholar 

  50. 50.

    Millar JL, Spry NA, Lamb DS, Delahunt J. Blindness in patients after external beam irradiation for pituitary ade-nomas: two cases occurring after small daily fractional doses. Clin Oncol 1991;3:291–294.

    Google Scholar 

  51. 51.

    al-Mefty O, Kersh JE, Routh A, Smith RR. The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg 1990;73:502–512.

    Google Scholar 

  52. 52.

    Grattan-Smith PJ, Morris JG, Langlands AO. Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumours. J Neurol Neurosurg Psych 1992;55:949–955.

    Google Scholar 

  53. 53.

    Thajeb P. Progressive late delayed postirradiation encephalopathy with Kluver-Bucy syndrome. Serial MRI and clinicopathologic studies. Clin Neurol Neurosurg 1995;97:264–268.

    Google Scholar 

  54. 54.

    Kleinschmidt-DeMaters BK. Necrotizing brainstem leukoencephalopathy six weeks following radiotherapy. Clin Neuropath 1995;14:63–68.

    Google Scholar 

  55. 55.

    Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980;6:1215–1218.

    Google Scholar 

  56. 56.

    Bliss P, Kerr GR, Gregor A. Incidence of second brain tumours after pituitary irradiation in Edinburgh 1962–1990. Clin Oncol 1994;6:361–363.

    Google Scholar 

  57. 56a.

    Jones A. Radiation oncogenesis in relation to the treatment of pituitary tumours. Clin Endocrinol 1991;3579–397.

  58. 57.

    Tsang RW, Lapperriere NJ, Simpson WJ, Brierley J, Panzarella T, Smyth HS. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 1993;72:2227–2233.

    Google Scholar 

  59. 57a.

    Brada M, Ford D, Ashley S, Mason M, Bliss J, Traish D, Rajon B, Proley S. Risk of second brain tumour following conservative surgery and radiotherapy of pituitary adenoma. B Med J 1992;304:1343–1346.

    Google Scholar 

  60. 58.

    Simmons NE, Laws ER Jr. Gioma occurrence after sellar irradiation: case report and review. Neurosurgery 1998;42: 172–178.

    Google Scholar 

  61. 59.

    Partington MD, Davis DH. Radiation-induced meningioma after treatment for pituitary adenoma: case report and literature review. Neurosurgery 1990;26:329–331.

    Google Scholar 

  62. 60.

    Suda Y, Mineura K, Kowada M, Ohishi H. Malignant astrocytoma following radiotherapy in pituitary adenoma: Case report. No Shinkei Geka Neurol Surg 1989;17:783–788.

    Google Scholar 

  63. 61.

    Liuzzi A, Oppizzi G. Evidence for octreotide subcutaneously in the treatment of acromegaly. J Endocrinol 1997;155: S61-S65.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jaffe, C.A. Reevaluation of Conventional Pituitary Irradiation in the Therapy of Acromegaly. Pituitary 2, 55–62 (1999). https://doi.org/10.1023/A:1009969921497

Download citation

  • growth hormone
  • adenoma
  • anterior pituitary
  • insulin-like growth factor I
  • neoplasia